LAVA Therapeutics NV LVTX 深 沪
等待开盘 04-02 09:30:00 美东时间
1.74
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.74
- 总市值 4577.12万
- 52周最高 2.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.8502
- 委 比 0.00%
- 总股本 2630.53万
- 历史最高 17.20
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.8502
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LAVA Therapeutics Extends Share Tender Deadline for XOMA Offer to November 12, 2025
XOMA Royalty Corporation has extended its offer to purchase all outstanding common shares of LAVA Therapeutics N.V. until one minute after 11:59 p.m. Eastern time on November 12, 2025. The extension f...
2025-11-11 05:14
XOMA and LAVA Therapeutics Announce Amendment To Purchase Agreement; LAVA Shareholders Who Tender Their Shares Will Now Receive An Initial Cash Amount Per Share Of $1.04; Amendment To Agreement With LAVA Includes Updated CVR Terms For Tender Offer
- Amendment includes finalized cash amount and updated CVR terms for tender offer- LAVA announces new date for extraordinary general meeting of shareholdersEMERYVILLE, Calif. and UTRECHT, The Netherlands and
2025-10-17 23:48
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
XOMA Royalty and LAVA announce the extension of the tender offer for LAVA shares until October 17, 2025, originally set for October 3. The offer includes cash and a contingent value right (CVR) per share. The transaction is expected to close in Q4 2025, subject to 80% (or 75% in certain cases) of shares being tendered, shareholder approval, and other customary conditions. LAVA shareholders who have already tendered shares do not need to re-tender...
2025-10-02 20:43
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025
LAVA Therapeutics has canceled its Extraordinary General Meeting (EGM) scheduled for September 30, 2025, to allow further discussions with XOMA Royalty regarding the terms of their proposed transaction. Both companies remain committed to completing the deal, which is now anticipated to close in the fourth quarter of 2025. The EGM will be reconvened by early November, with details to be announced later. The cancellation aims to address potential l...
2025-09-30 11:00
4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week
Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline.
2025-09-03 18:21
美股大行评级 | 潜在涨幅345.51%！BTIG上调Syndax Pharmaceuticals目标价至56美元，维持"买入"评级
今日重点评级关注：BTIG：维持Syndax Pharmaceuticals"买入"评级，目标价从43美元升至56美元；花旗：维持Syndax Pharmaceuticals"买入"评级，目标价从46美元升至51美元
2025-08-06 09:30
Jefferies Downgrades LAVA Therapeutics to Hold, Lowers Price Target to $1.5
Jefferies analyst Roger Song downgrades LAVA Therapeutics (NASDAQ:LVTX) from Buy to Hold and lowers the price target from $3 to $1.5.
2025-08-05 18:43
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, HNI, LVTX, HLVX on Behalf of Shareholders
NEW YORK, Aug. 4, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or ...
2025-08-05 00:23
LAVA Therapeutics Agrees to Acquisition by XOMA
The latest announcement is out from LAVA Therapeutics ( ($LVTX) ). On August 3,...
2025-08-04 19:58
BRIEF-XOMA Royalty to acquire LAVA Therapeutics for $1.16-$1.24 per share
Aug 4 (Reuters) - LAVA Therapeutics NV LVTX.O: XOMA ROYALTY ENTERS INTO AGREEMENT TO ACQUIRE LAVA THERAPEUTICS FOR BETWEEN $1.16 AND $1.24 PER SHARE IN CASH, PLUS A CONTINGENT VALUE RIGHT XOMA ROYALTY...
2025-08-04 19:42
